Funder
National Heart, Lung, and Blood Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Cardiology and Cardiovascular Medicine,Pharmaceutical Science,Genetics,Molecular Medicine
Reference29 articles.
1. Fayssoil, A., Nardi, O., Orlikowski, D., & Annane, D. (2010). Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics. Heart Failure Reviews., 15(1), 103–107.
2. Gumerson, J. D., & Michele, D. E. (2011). The dystrophin-glycoprotein complex in the prevention of muscle damage. Journal of biomedicine & biotechnology., 2011, 210797.
3. D’Amario, D., Amodeo, A., Adorisio, R., Tiziano, F. D., Leone, A. M., Perri, G., et al. (2017). A current approach to heart failure in Duchenne muscular dystrophy. Heart (British Cardiac Society)., 103(22), 1770–1779.
4. Kamdar, F., & Garry, D. J. (2016). Dystrophin-deficient cardiomyopathy. Journal of the American College of Cardiology, 67(21), 2533–2546.
5. Siemionow, M., Cwykiel, J., Heydemann, A., Garcia-Martinez, J., Siemionow, K., & Szilagyi, E. (2018). Creation of dystrophin expressing chimeric cells of myoblast origin as a novel stem cell based therapy for Duchenne muscular dystrophy. Stem cell reviews., 14(2), 189–199.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献